Sepsis, October 27 edition

This mechanistic study identifies ROS-driven palmitoylation of GSDMD by ZDHHC5/ZDHHC9 as a previously unrecognized amplifier of canonical and non-canonical pyroptosis in sepsis. Optimized vanadium oxide hydroxide nanosheets suppressed this modification, reduced inflammatory tissue injury, and improved outcomes in two animal models, with GSDMD-knockout experiments supporting target specificity.

Impact: The study provides a new, chemically targetable regulatory layer upstream of GSDMD-mediated pyroptosis and combines patient-derived evidence, nanomaterial optimization, multiple animal models, and genetic validation. It therefore offers a strong mechanistic foundation for future host-directed sepsis therapy, although clinical translation remains distant.

Clinical Implications: The findings support development of ROS-scavenging nanocatalysts or selective inhibitors of GSDMD palmitoylation as potential adjunctive treatments. Translation will require pharmacokinetic, biodistribution, toxicity, infection-control, and survival studies in clinically relevant models before human trials.

Future Directions: Future work should define the pharmacokinetic and tissue-distribution profiles of the nanosheets, assess immunotoxicity and effects on pathogen clearance, establish therapeutic rather than prophylactic dosing, and test efficacy in larger clinically representative models before phase I studies.

Using 209 ICU patients, CLP mice, endothelial-specific Ezh2 knockout mice, pharmacologic interventions, and multi-omics, this study identifies site-specific EZH2 K30/K406 lactylation as a lactate-responsive mechanism in sepsis-associated lung injury. EZH2 lactylation reduced CITED2 promoter occupancy, released NF-κB activity, and worsened pulmonary inflammation and endothelial dysfunction, while inhibition of lactate production or EZH2 lactylation improved lung injury.

Impact: The paper connects a clinically measurable metabolic abnormality, elevated lactate, to a specific post-translational epigenetic modification and a defined inflammatory transcriptional pathway. The combination of human association, endothelial cell-specific genetics, and mechanistic intervention substantially strengthens the case for EZH2 lactylation as a therapeutic target.

Clinical Implications: Lactate kinetics may help identify patients with lactate-driven lung injury, while enzymes or molecular interfaces controlling EZH2 lactylation could become therapeutic targets. These implications remain investigational because the patient component is observational and no site-specific inhibitor has yet been clinically tested.

Future Directions: Future studies should validate EZH2 lactylation in independent longitudinal patient cohorts, define the enzymes responsible for adding and removing the modification, develop site-selective inhibitors, and determine whether treatment preserves antimicrobial host defense while reducing lung injury.

In this five-ICU open-label randomized trial of 485 older adults with sepsis receiving invasive mechanical ventilation, restricting restraints to severe agitation did not improve the primary outcome of days alive without delirium or coma. However, the low-use strategy increased ventilator-free days by 0.69 days and coma-free days by 0.46 days without significant differences in delirium incidence, sedative exposure, mortality, or reported safety outcomes.

Impact: This is one of the largest randomized evaluations of a restraint-minimization strategy in older septic patients receiving mechanical ventilation and addresses an ethically important, widely used ICU practice. The neutral primary outcome combined with favorable short-term recovery signals provides balanced evidence against routine restraint use while highlighting unresolved safety questions.

Clinical Implications: ICUs may consider replacing routine restraint with an individualized strategy reserved for severe agitation, combined with delirium prevention, sedation minimization, close observation, and staff training. The findings do not justify unrestricted restraint avoidance because the trial was open-label and safety outcomes were not significantly improved.

Future Directions: Future trials should use standardized safety definitions, measure unplanned device removal and self-harm, incorporate delirium and sedation protocols, and evaluate implementation across diverse ICUs. Longer-term outcomes such as functional recovery, post-intensive care cognitive impairment, and caregiver burden should also be assessed.